Date: 2012-11-02
Type of information: Grant
Company: Dilaforette (Sweden)
Investors: Vinnova, Swedish Governmental Agency for Innovation Systems (Sweden)
Amount: SEK 2.85 million (€ 0.3 million)
Funding type: grant
Planned used: The grant will be used for development of sevuparin for the treatment of severe malaria.
Others: Dilaforette, a Swedish drug development company developing sevuparin, a heparin analogue for the treatment of severe malaria and sickle cell disease, has been granted SEK 2.85m (€ 0.3 million) from the Swedish Governmental Agency for Innovation Systems, Vinnova, for the development of sevuparin, a new potential treatment for severe malaria. Sevuparin is intended as an adjunctive therapy to anti-parasite medicines in order to prevent the infected red blood cells from obstructing blood vessels and thereby reducing mortality.
The grant will be used for process and method development and validation. The project is in Phase II with a clinical study ongoing in Thailand in collaboration with leading malaria clinicians at the Mahidol Oxford Tropical Medicine Research Unit, which is supported by the Wellcome Trust.
Therapeutic area: Infectious diseases
